



Sèvres, 19 January 2012

CFAO announced today the appointment of Jean-Marc Leccia to the post of Chairman and CEO of Eurapharma with effect from 1 July 2012. Eurapharma is the CFAO's Group division dedicated to pharmaceutical distribution on the African continent and in the French Overseas Departments and Territories. Jean-Marc Leccia will be replacing Jean-Yves Mazon who will continue to serve as a Member of the Executive Board of the CFAO Group until his term of office expires.

Aged 46, Jean-Marc Leccia is a graduate of EPSCI and began his career with Laboratoires Baxter, responsible for exports in Africa. He went on to join Eurapharma in 1991 where he was responsible for promotional activities and then, in 2000, set up the Pre-Wholesale business Epdis France. Since 2005 Jean-Marc Leccia has also been in charge of developing and supervising the growth of Eurapharma business activities in English-speaking and Portuguese-speaking Africa as well as in Algeria.

### **About CFAO**

CFAO is the foremost specialized retail brand in its main business areas – vehicle and pharmaceuticals distribution – in Africa and the French overseas territories. It is a leading player in these regions in the import and distribution of vehicles and pharmaceutical products, related logistical services, and certain manufacturing operations and technological services. CFAO is present in 34 countries, 31 of which are in Africa and seven in the French overseas territories, and had a headcount of 9,240 at end-2010.

In 2010, CFAO generated consolidated revenue of €2,676 million and recorded recurring operating income of €223.2 million.

CFAO is listed on NYSE Euronext in Paris and is included in the SBF120 and CAC Mid 60 indices.

Find CFAO on Bloomberg: CFAO:FP and Reuters: CFAO.PA

To find out more, go to [www.cfaogroup.com](http://www.cfaogroup.com)

## **Press Relations**

Laurence Tovi  
Communications Vice-President  
+33 1 46 23 58 80

## **Investor and Analyst Relations**

Sébastien Desarbres  
Director of Financial Communications and Investor Relations  
+33 1 46 23 56 51